RxDoctor Payments Data

Trieu Dang, DPM

Podiatrist · Jacksonville, FLNPI 1801204755

Payments from drug & device makers

$1,047in general payments, 2019–2025

Across 31 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$379
  • Smith+Nephew$197
  • Kerecis Limited$59
  • Organogenesis Inc.$56
  • Paratek Pharmaceuticals, Inc.$55
  • IBSA Pharma Inc.$42
  • plus $259 from 10 others

What the payments were for

  • Food & beverage$1,047100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)5$379
Smith+Nephew6$197
Kerecis Limited2$59
Organogenesis Inc.2$56
Paratek Pharmaceuticals, Inc.3$55
IBSA Pharma Inc.2$42
Next Science LLC1$41
Nevro Corp.2$39
Convatec Inc.1$32
Omeza LLC1$31
Biowound Solutions, Inc.1$29
Apria Healthcare LLC1$23
Orthofix Medical, Inc.1$20
Reprise Biomedical, Inc.1$16
Averitas Pharma Inc.1$15
Zyla Life Sciences, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,047 in reported general payments places this provider in the 50th percentile of 588 podiatrist providers in Florida.

See all podiatrist providers in Florida

Medicare billing

Part B allowed, 2024
$99,720
Medicare patients
499
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.27$8,109
Betamethasone Dipropionate21$426
Cephalexin63$407
Doxycycline Hyclate39$368
Ciprofloxacin Hcl20$192
Ketoconazole19$192
Silver Sulfadiazine26$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$197$8,10927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 588 podiatrist providers in Florida.

Other podiatrist in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →